Guardant Health to Present at the 38th Annual J.P. Morgan Healthcare Conference
December 30, 2019 16:05 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif., Dec. 30, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming...
Guardant Health Receives Expanded Medicare Coverage for Guardant360 Across the Vast Majority of Solid Tumor Cancers
December 19, 2019 13:45 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), announced that Palmetto GBA, a Medicare Administrative Contractor for the Molecular Diagnostics (MolDX)...
Large-Scale Study Shows Guardant360 Effectively Guides Precision Oncology Treatment in Metastatic Breast Cancer Patients
December 13, 2019 08:15 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif., Dec. 13, 2019 (GLOBE NEWSWIRE) -- In the largest-ever liquid biopsy study for treatment selection in advanced breast cancer, investigators demonstrated in an 800-patient...
Study Shows Only 40 Percent of Patients with Metastatic Colon Cancer Receive Guideline-Recommended Biomarker Testing
December 11, 2019 08:15 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Despite longstanding medical guidelines recommending biomarker testing for all patients with metastatic colon cancer, a new study published in...
Guardant Health Reports Third Quarter 2019 Financial Results and Raises 2019 Revenue Guidance
November 07, 2019 16:03 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its...
Guardant Health to Report Third Quarter 2019 Financial Results on November 7, 2019
November 04, 2019 16:05 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the third quarter 2019 after market close on Thursday,...
Guardant Health Initiates ECLIPSE Pivotal Study for its LUNAR-2 Blood Test for Colorectal Cancer Screening
October 23, 2019 16:03 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) has initiated the ECLIPSE trial, a 10,000-patient registrational study to evaluate the performance of its...
Data Presented at ESMO Show Metastatic CRC Patients with HER2 Amplification Detected by Guardant360 Experience Clinical Benefit After Targeted Therapy
September 28, 2019 13:05 ET
|
Guardant Health, Inc.
BARCELONA, Spain, Sept. 28, 2019 (GLOBE NEWSWIRE) -- Guardant Health and the National Cancer Center Hospital East will present data at the European Society of Medical Oncology (ESMO) conference from...
Guardant Health Reports Second Quarter 2019 Financial Results and Raises 2019 Revenue Guidance
August 06, 2019 16:05 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its...
Largest Study of its Kind Finds Guardant360 MSI Highly Concordant to Tissue
August 05, 2019 08:00 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- In the largest comparison of blood-based microsatellite instability (MSI) testing to traditional tissue methods across multiple solid tumor...